Gsa Capital Partners LLP Biocryst Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

$1.35 Billion
Q4 2024

A detailed history of Gsa Capital Partners LLP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 164,484 shares of BCRX stock, worth $1.43 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

164,484

Previous 285,588 42.41%

Holding current value

$1.43 Million

Previous $2.17 Million 43.0%

% of portfolio

0.09%

Previous 0.16%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	SELL	$7.03 - $8.43 $851,361 - $1.02 Million	-121,104 Reduced 42.41%	164,484 $1.24 Million
Q3 2024 Nov 05, 2024	SELL	$6.41 - $8.69 $501,582 - $679,992	-78,250 Reduced 21.51%	285,588 $2.17 Million
Q2 2024 Aug 15, 2024	BUY	$4.13 - $6.79 $1.5 Million - $2.47 Million	363,838 New	363,838 $2.25 Million
Q4 2023 Feb 16, 2024	SELL	$4.98 - $6.77 $63,534 - $86,371	-12,758 Reduced 6.66%	178,769 $1.07 Million
Q3 2023 Nov 15, 2023	BUY	$6.71 - $7.92 $805,166 - $950,360	119,995 Added 167.75%	191,527 $1.36 Million
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $572,014 - $724,058	-82,186 Reduced 53.47%	71,532 $503,000
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $1.22 Million - $1.82 Million	153,718 New	153,718 $1.28 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $206,315 - $283,182	19,121 New	19,121 $241,000
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $459,676 - $635,653	-41,116 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$14.21 - $17.65 $584,258 - $725,697	41,116 New	41,116 $591,000
Q2 2021 Aug 05, 2021	SELL	$9.5 - $17.24 $761,871 - $1.38 Million	-80,197 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$7.37 - $13.61 $513,666 - $948,576	69,697 Added 663.78%	80,197 $816,000
Q4 2020 Feb 03, 2021	BUY	$3.37 - $8.61 $35,385 - $90,405	10,500 New	10,500 $78,000
Q3 2020 Nov 06, 2020	SELL	$3.43 - $5.53 $135,824 - $218,982	-39,599 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$1.9 - $5.61 $188,223 - $555,754	-99,065 Reduced 71.44%	39,599 $189,000
Q1 2020 May 12, 2020	BUY	$1.6 - $4.11 $221,862 - $569,909	138,664 New	138,664 $277,000
Q2 2019 Aug 06, 2019	SELL	$2.91 - $9.15 $117,514 - $369,504	-40,383 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $298,026 - $392,522	40,383 New	40,383 $329,000
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $54,437 - $69,748	-13,086 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$4.1 - $5.97 $53,652 - $78,123	13,086	13,086 $69,000

Others Institutions Holding BCRX

# of Institutions

285

Shares Held

171M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.62B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Biocryst Pharmaceuticals Inc Transaction History